✦ LIBER ✦

ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development

✍ Scribed by Giorgio Scagliotti; Rolf A. Stahel; Rafael Rosell; Nick Thatcher; Jean-Charles Soria

Book ID: 116431026
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 892 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.02.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity and safety of crizotinib in pat

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

✍ D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella- 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 310 KB

PCN73 Economic Analysis of the Use of Cr

PCN73 Economic Analysis of the Use of Crizotinib, a Tyrosine Kinase ALK Inhibitor, in the Treatment of ALK Positive Non-Small Cell Lung Cancer in the Mexican Setting

✍ J.G. Gay-Molina; R. Sánchez-Kobashi; E. Muciño-Ortega; C.I. Gutiérrez-Colín; R.M 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Drug development in patients with advanc

Drug development in patients with advanced non-small cell lung cancer and poor performance status

✍ Thomas E. Stinchcombe; Mark A. Socinski 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Elucidation of Relationship Between Tumo

Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

✍ Wang, Y; Sung, C; Dartois, C; Ramchandani, R; Booth, B P; Rock, E; Gobburu, J 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 228 KB

Phase II study of N-methylformamide, spi

Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): An Eastern cooperative oncology group study

✍ Ettinger, David S. ;Finkelstein, Dianne M. ;Donehower, Ross C. ;Chang, Alex Y. C 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 407 KB

One hundred forty-four patients with non-small cell lung cancer, the majority (72%) of whom had received previous chemotherapy, were evaluable in this randomized phase II study of N-methylformamide (N-MF), spirogermanium, and 4-demethoxydaunorubicin. There were two partial responses, one each with s

Phase II study of irinotecan and docetax

Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007)

✍ Grossi, Francesco; Fasola, Gianpiero; Rossetto, Ciro; Spizzo, Riccardo; Meduri, 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 105 KB